Use of topical ketanserin in the treatment of skin ulcers: a double-blind study

J Am Acad Dermatol. 1989 Jul;21(1):85-90. doi: 10.1016/s0190-9622(89)70153-5.


The use of a 2% ointment formulation of ketanserin, an S2-serotoninergic blocking agent, was investigated in a randomized double-blind clinical trial for its effect on the healing of wounds of patients with decubitus, venous, and ischemic skin ulcers. The result demonstrates a significant difference in favor of the ketanserin-treated group (35 patients) versus the placebo-treated group (37 patients) on the basis of two factors: formation of granulation tissue and epithelialization. In addition, a significant difference of 150% in the initial velocity of wound closure was observed in favor of the patients treated with ketanserin. This effect was persistent during the entire study period.

Publication types

  • Clinical Trial
  • Multicenter Study
  • Randomized Controlled Trial

MeSH terms

  • Administration, Cutaneous
  • Adult
  • Aged
  • Aged, 80 and over
  • Double-Blind Method
  • Female
  • Humans
  • Ischemia
  • Ketanserin / administration & dosage
  • Ketanserin / therapeutic use*
  • Male
  • Middle Aged
  • Multicenter Studies as Topic
  • Placebos
  • Pressure Ulcer / drug therapy
  • Random Allocation
  • Skin Ulcer / drug therapy*
  • Skin Ulcer / pathology
  • Varicose Ulcer / drug therapy
  • Wound Healing


  • Placebos
  • Ketanserin